Lobbying Expenditures in the US Health Care Sector, 2000-2020-Reference-Cited by-同舟云学术

Lobbying Expenditures in the US Health Care Sector, 2000-2020

Published:2022-10-28 Issue:10 Volume:3 Page:e223801
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Schpero William L.¹,Wiener Thomas¹,Carter Samuel¹,Chatterjee Paula²³

Affiliation:

1. Division of Health Policy and Economics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York

2. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

3. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia

Abstract

This cross-sectional study uses publicly available, nonpartisan data to evaluate trends in lobbying expenditures across health care industries.

Publisher

American Medical Association (AMA)

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://jamanetwork.com/journals/jama-health-forum/articlepdf/2797734/schpero_2022_ld_220032_1666118272.95917.pdf

Reference6 articles.

1. Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018.;Wouters;JAMA Intern Med,2020

2. Lobbying, campaign contributions, and health care reform.;Steinbrook;N Engl J Med,2009

3. Bill profile: H.R. 3630. OpenSecrets. Accessed May 26, 2022. https://www.opensecrets.org/federal-lobbying/bills/summary?id=hr3630-116

4. Research tools. OpenSecrets. Accessed May 26, 2022. https://www.opensecrets.org/research-tools

5. Section 4—lobbying registration. Office of the Clerk, US House of Representatives. Accessed May 26, 2022. https://lobbyingdisclosure.house.gov/amended_lda_guide.html#section4

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lobbying in US Health Care—Lessons From the Field of Oncology;Journal of the National Comprehensive Cancer Network;2024-05

2. Policy Issues in the Care of Older Adults;Geriatric Medicine;2024

3. Claims, Conflicting Claimants, and Their Reasoning;Embryonic Stem Cells and the Law;2024

4. Implications of IR Being a Primary Specialty on the Professional Organizational Relationship between Interventional and Diagnostic Radiology;Journal of Vascular and Interventional Radiology;2023-12

5. Understanding the US Health Care Industry as a Commercial Determinant of Health;JAMA Health Forum;2023-07-13